Sustained inflammation and matrix metalloproteinase (MMP) activation contribute to vascular occlusive/proliferative disorders. Interleukin-17 (IL-17) is a proinflammatory cytokine that signals mainly via TRAF3 Interacting Protein 2 (TRAF3IP2), an upstream regulator of various critical transcription factors, including AP-1 and NF-κB. Reversion inducing cysteine rich protein with kazal motifs (RECK) is a membrane-anchored MMP inhibitor. Here we investigated whether IL-17A/TRAF3IP2 signaling promotes MMP-13dependent human aortic smooth muscle cell (SMC) proliferation and migration, and determined whether RECK overexpression blunts these responses. Indeed, IL-17A treatment induced (a) JNK, p38 MAPK, AP-1, NF-κB, and CREB activation, (b) miR-21 induction, (c) miR-27b and miR-320 inhibition, (d) MMP-13 expression and activation, (e)
RECK suppression, and (f) SMC migration and proliferation, all in a TRAF3IP2-dependentAbbreviations: Act1, NFκB-activating protein-1; Ad.GFP, adenoviral vector expressing green fluorescent protein; ADAM, a disintegrin and metalloproteinase domain-containing protein 10;Ang, angiotensin; AP-1, activator protein-1; ASK1, apoptosis signal regulating kinase 1; C/EBPβ, CCAAP enhancer binding protein beta; cAMP, 3′,5′-cyclic adenosine monophosphate; CIKS, connection to connection to IKK and SAPK/JNK; CREB, cAMP responsive element binding protein; DES, drug-eluting stents; DMSO, dimethyl sulfoxide; ECM, extracellular matrix; EGFR, epidermal growth factor receptor; ERK, extracellular regulated kinase; FAK, focal adhesion kinase; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; GBM, glioblastoma multiforme; GPI, glycosylphosphatidylinositol; IL, interleukin; ISR, in-stent restenosis; ITS, insulin-transferrin-sodium selenite; JNK, c-jun N-terminal kinase; MAPK, mitogen-activated protein kinase; MCP-1, macrophage chemotactic protein-1; miR, microRNA; MMP, matrix metalloproteinase; moi, multiplicity of infection; MT1-MMP, membrane-type-1 matrix metalloproteinase; MTT, 3-(4,5dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; PDGF, platelet-derived growth factor; qPCR, quantitative polymerase chain reaction; RECK, reversion-inducing cysteine-rich protein with kazal motifs; rMMP-13, recombinant biologically active human MMP-13; shRNA, short-hairpin RNA; SM-MHC, smooth muscle myosin heavy chain; SMC, smooth muscle cells; TACE, tumor necrosis factor-α-converting enzyme; TGF, transforming growth factor; TNF, tumor necrosis factor; TRAF, TNF receptor-associated factor; TRAF3IP2, TRAF3 interacting protein 2; UTR, untranslated region; VWF, Von Willebrand factor; αSMA, α smooth muscle actin.